International Clinical Trial: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07725939) titled 'A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis' on July 21.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: UCB Biopharma SRL

Condition: Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

Intervention: Biological: Galvokimig

Recruitment Status: Not recruiting

Phase:...